- 专利标题: Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
-
申请号: US10730643申请日: 2003-12-08
-
公开(公告)号: US07057027B2公开(公告)日: 2006-06-06
- 发明人: Brian Froehler , Rick Wagner , Mark Mattencci , Robert J. Jones , Arnold J. Gutierrez , Jeff Pudlo
- 申请人: Brian Froehler , Rick Wagner , Mark Mattencci , Robert J. Jones , Arnold J. Gutierrez , Jeff Pudlo
- 申请人地址: US CA Carlsbad
- 专利权人: ISIS Pharmaceuticals, Inc.
- 当前专利权人: ISIS Pharmaceuticals, Inc.
- 当前专利权人地址: US CA Carlsbad
- 代理机构: Woodcock Washburn LLP
- 主分类号: C07H21/00
- IPC分类号: C07H21/00 ; C07H21/02 ; C07H21/04
摘要:
Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention. Compositions of the invention can be used as pharmaceutical agents to treat various diseases such as those caused by viruses and can be used for diagnostic purposes in order to detect viruses or disease conditions.
公开/授权文献
信息查询